Use of Vasopressin Following the Fontan Operation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02975999|
Recruitment Status : Suspended (Pilot study is finished, multi centered is awaiting funding)
First Posted : November 29, 2016
Last Update Posted : January 12, 2018
|Condition or disease||Intervention/treatment||Phase|
|Pleural Effusion Single-ventricle||Drug: Vasopressin Drug: Normal Saline||Phase 2 Phase 3|
A pilot and subsequently a multicenter, randomized, double blinded clinical trial to evaluate the use of vasopressin following the Fontan operation.
Phase one of the study will be a single center pilot study and will be conducted at Advocate Children's Hospital, Oak Lawn IL. This will be a randomized and double blinded. Ten patients will be enrolled with five patients as control group and five receiving Vasopressin. Vasopressin levels will be obtained just prior to initiation of Vasopressin and 48 hours later in the pilot study. Safety and effect size will be evaluated after this pilot study.
The multicenter study will be phase two and will be conducted in the cardiac operating rooms and cardiac intensive care unit (CVICU) of 7 pediatric cardiovascular programs in the United States. The investigators will be enrolling 12 subjects undergoing the Fontan operation from each participating institution. Six patients will be randomly assigned to receive Vasopressin while six will receive placebo.
A total of 84 patients undergoing the Fontan operation will be included in the study and randomized to one of the two treatment groups.
Group 1 will include 42 subjects who will receive the treatment drug (Vasopressin) for 48 hours following the Fontan operation. Group 2 will include 42 subjects who will receive placebo (normal saline) and will serve as a control group.
Drug administration protocol:
Vasopressin at a dose of 0.4 mU/kg/min will be started on subjects in the study group while coming off cardiopulmonary bypass. The dose of Vasopressin will not be titrated. Study drug drip will infuse for 48 hours after which will be discontinued.
The placebo group will be receiving normal saline at the same rate of the vasopressin group. The treating physician will be blinded.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||84 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Use of Vasopressin Following the Fontan Operation: Both Pilot and Multicenter Studies|
|Study Start Date :||December 2016|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
Vasopressin at 0.4mU/kg/min
Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Other Name: Vasostrict, arginine
Placebo Comparator: Normal saline
Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation.
Drug: Normal Saline
Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Other Name: Placebo
- Chest tube drainage [ Time Frame: From post operative day 0 through study completion, an average of 1 month ]chest tube drainage in ml/kg/day until the day the chest tube is removed
- Length of hospital stay [ Time Frame: From the day of the surgery (post operative day 0) through study completion, an average of 1 month ]Duration the patient remains in the hospital in days until the day of discharge home
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02975999
|United States, Illinois|
|Advocate Children's Hospital|
|Oak Lawn, Illinois, United States, 60453|